launched a generic version of
Actiq cancer pain management product.
Barr launched the product under the terms of a license agreement previously granted to Barr by Cephalon in August 2004. The license grants Barr a non-exclusive right to sell a generic version of Actiq. Under the terms of the agreement, Cephalon is currently supplying Barr with fentanyl citrate manufactured under Cephalon's New Drug Application, which Barr then has the right to sell and market.
Actiq is indicated for the treatment of breakthrough cancer pain in opioid tolerant patients and has current annual sales of about $590 million.
The shares of the company were trading up 27 cents at $51.96, Wednesday.
This story was created through a joint venture between TheStreet.com and IRIS.